CNS vs IVZ: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
CNS and IVZ are similarly sized, but IVZ trades noticeably cheaper on forward earnings (9.14x vs 21.15x): the market is paying up for CNS's profile and pricing IVZ more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
CNS vs IVZ: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CNS | IVZ | What it tells you |
|---|---|---|---|
| Forward P/E | 21.15 | 9.14 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.22 | 1.60 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 90% of range | 87% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 7.51 | 1.05 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: IVZ is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how CNS and IVZ affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CNS and IVZ share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CNS and IVZ exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Cohen & Steers (CNS) do?
Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. It organized the first US real estate securities mutual fund and remains one of the largest managers of REIT securities in the world, with roughly two-thirds of assets in listed real estate. The firm earns management fees on the assets it runs across open-end funds, closed-end funds, institutional accounts, and newer vehicles like its non-traded REIT (CNSREIT).
What does Invesco Ltd (IVZ) do?
Invesco Ltd. is a global independent investment management firm that manages money for retail and institutional clients across equities, fixed income, alternatives, and multi-asset strategies. It distributes through mutual funds, separately managed accounts, institutional mandates, and a large ETF business, and it is best known as the sponsor of Invesco QQQ, one of the largest and most heavily traded ETFs in the world. Because it earns fees on the assets it manages, Invesco's revenue moves with two things: the level of markets (which lifts or lowers asset values) and net client flows (money coming in or leaving).
CNS vs IVZ: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- CNS drivers: Rate-cut tailwind for real assets; Return to organic growth.
- IVZ drivers: QQQ conversion unlocks new fees; Record AUM and durable inflows.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. For IVZ, the dominant risk is market sensitivity: as a fee-on-assets business, Invesco's revenue and profits fall when equity and bond markets drop, so a sustained downturn would cut AUM and earnings quickly regardless of execution.
CNS or IVZ: which should you pick?
CNS vs IVZ: the full fundamentals
CNS. As of April 2026, CNS traded around a mid-20s price-to-earnings multiple with a dividend yield near 3.7%, reflecting its status as a profitable, dividend-paying specialty manager. Q1 2026 revenue of about $145.6 million grew roughly 8% year over year, and operating margin improved to about 34%. Because fees scale with AUM, valuation and earnings hinge on the direction of markets and flows into real-asset strategies.
IVZ. Figures are approximate and tied to the asOf date; verify live numbers before acting. For an asset manager, AUM, flows, and fee rate matter more than a single quarter's EPS, because revenue is driven by average assets under management across the period. The QQQ conversion is a genuine earnings catalyst but its full-year revenue impact will take time to show up, so watch reported management-fee revenue in coming quarters. The stock re-rated toward 52-week highs on the QQQ news, so some optimism is already priced in.
Headline figures (approximate, APRIL 2026): CNS shows assets under management ~$93.1B, revenue (q1 2026) ~$145.6M, q1 2026 net inflows ~$497M, diluted eps (q1 2026) ~$0.82; IVZ shows operating revenue (q1 2026) ~$1.74 billion, up ~14% year over year, adjusted diluted eps (q1 2026) ~$0.57 (GAAP diluted ~$0.51), total aum (q1 2026) record ~$2.16 trillion, up ~17% year over year, net long-term inflows (q1 2026) ~$21.8 billion, an ~4.4% annualized organic growth rate; 11th straight positive quarter.
The bottom line: CNS vs IVZ
CNS and IVZ are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CNS and IVZ exposure against your real portfolio. It is not an investment adviser.
Wondering how CNS or IVZ fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Cohen & Steers with AI
Connect the broker you already use and ask Walnut's AI how CNS fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between CNS and IVZ?
+
Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. Invesco Ltd. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CNS or IVZ the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CNS or IVZ?
+
On forward P/E (as of August 2026), CNS trades at 21.15x and IVZ at 9.14x, so IVZ is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CNS and IVZ?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CNS vs IVZ?
+
CNS: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. Its concentration in real estate and rate-sensitive income means a reversal to higher-for-longer rates, or a rotation away from REITs and preferreds, could trigger outflows and market depreciation at the same time. The active-management fee model faces secular pressure from low-cost passive and index products, and net flows can turn negative in stressed markets. Newer private and non-traded initiatives add execution and liquidity risk, and results can be lumpy quarter to quarter. IVZ: The dominant risk is market sensitivity: as a fee-on-assets business, Invesco's revenue and profits fall when equity and bond markets drop, so a sustained downturn would cut AUM and earnings quickly regardless of execution. Fee compression is structural, with passive and ETF price wars (Invesco itself is cutting the QQQ fee) pressuring industry margins over time. Flows can reverse: eleven quarters of inflows can turn to outflows if performance lags or sentiment shifts. Heavy reliance on a single flagship product, QQQ, concentrates risk in the Nasdaq-100 and the tech-heavy names that drive it, and QQQ also faces new ETF competition. The private-markets push adds execution and partnership-dependency risk, and the firm carries debt and prior preferred obligations that constrain flexibility in a downturn.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CNS or IVZ; figures are approximate and dated (as of August 2026). Verify current data before investing.